Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company's products in development include BonoFill for bone tissue regeneration in maxillofacial and orthopedic indications and is in Phase II clinical trial; and MesenCure for the treatment of COVID patients suffering from pneumonia and ARDS and is in phase III trial. Its products in pipeline also comprise BonoFill for bone augmentation in osteoporosis patients; MesenCure for treating other inflammations and tissue damage; vascularized bone grafts; and soft tissue grafts. The company was formerly known as Oceana Advanced Industries Ltd. Bonus BioGroup Ltd. was incorporated in 1981 and is based in Haifa, Israel.
| 0.04 | |
| 0.04 | |
| - | |
| 0.04 | |
| 0.04 | |
| 0.0003-0.055 | |
| 48 641 K | |
| 1 168 M | |
| 0 | |
| -0.0019 | |
| 1.04 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Bonus BioGroup (TASE: BONS), a clinical-stage Israeli biotechnology company engaged in the research and development of biomedical tissue-engineered and cell therapy products, has discovered that its C...
POET Technologies Inc. Management to Host Business Update Conference Call on April 27 TORONTO, April 21, 2022 (GLOBE NEWSWIRE) -- POET Technologies Inc. (“POET” or the “Company”) (TSX Ventur...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
